<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00811538</url>
  </required_header>
  <id_info>
    <org_study_id>233/07</org_study_id>
    <secondary_id>1446</secondary_id>
    <secondary_id>KEK 233/07</secondary_id>
    <nct_id>NCT00811538</nct_id>
  </id_info>
  <brief_title>Swiss Intravenous and Intra-arterial Thrombolysis for Treatment of Acute Ischemic Stroke Registry</brief_title>
  <acronym>SWISS</acronym>
  <official_title>Swiss Intravenous and Intra-arterial Thrombolysis for Treatment of Acute Ischemic Stroke Registry (SWISS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Inselspital, Berne</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Swiss Heart Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Zurich</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital, Basel, Switzerland</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital, Geneva</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Lausanne Hospitals</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Kantonsspital Aarau</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Cantonal Hospital of St. Gallen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Triemli Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital Inselspital, Berne</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The clinical and radiological data of patients with an acute ischemic stroke treated with&#xD;
      intravenous thrombolysis (IVT) or intraarterial thrombolysis (IAT) in a Swiss stroke unit are&#xD;
      assessed in a Swiss Multicenter Thrombolysis Registry. Like in clinical routine, a clinical&#xD;
      evaluation takes place in a 3-months follow-up. Furthermore quality of life is assessed with&#xD;
      a standardized questionnaire. The aim of the registry is to compare the safety and efficacy&#xD;
      of IVT and IAT in patients with acute ischemic stroke. The registry also helps to improve&#xD;
      in-hospital-management of stroke patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background: Intravenous thrombolysis (IVT) and intra-arterial thrombolysis (IAT) have been&#xD;
      shown to be effective treatments for acute stroke in controlled randomized trials and&#xD;
      meta-analyses. However, prospective studies comparing IVT and IAT have not been performed,&#xD;
      and it is not known which patients benefit more from IVT or IAT. Non-invasive neurovascular&#xD;
      imaging techniques such as magnetic resonance angiography (MRA) or computed tomography&#xD;
      angiography (CTA) have the potential to improve patient selection for the optimal mode of&#xD;
      thrombolytic therapy and provide data of pre-treatment neurovascular findings of patients&#xD;
      treated with IVT. IAT series have identified several prognostic factors for favourable or&#xD;
      poor outcome predictors such as vessel recanalization, location of the vascular occlusion or&#xD;
      NIHSS at admission. Additional studies have shown that recanalization rates in patients with&#xD;
      central ves-sel occlusions such as middle cerebral artery (MCA) main stem or MCA main branch&#xD;
      or basilar artery (BA) is higher when treated with IAT compared to IVT. Therefore, the&#xD;
      investigators hypothesize that IAT might be more efficacious in these patients.&#xD;
&#xD;
      Objective: Prospective observational multicenter registry with the following aims: To compare&#xD;
      the safety and efficacy of IAT and IVT in patients with acute ischemic stroke. To improve&#xD;
      safety of IAT and IVT by monitoring the in-hospital management.&#xD;
&#xD;
      Methods: Consecutive patients with acute ischemic stroke who are treated with IVT or IAT&#xD;
      within 6 hours of symptom onset in a Swiss stroke unit will be eligible for this registry.&#xD;
      Patients are given either intravenous rt-PA or receive IAT such as intra-arterial urokinase,&#xD;
      intra-arterial rt-PA or mechanical endovascular recanalization techniques. Patient&#xD;
      involvement in the registry shall not influence any treatment decision. Patients will undergo&#xD;
      a complete diagnostic work up including a clinical neurological examination using the&#xD;
      National Institutes of Health Stroke Scale (NIHSS) score on admission, laboratory&#xD;
      examination, brain and neurovascular imaging, echocardiography, 24-hours ECG to determine&#xD;
      stroke etiology using the Trial of Org 10172 in Acute Stroke Treatment (TOAST) criteria. The&#xD;
      treating physician will initiate secondary prevention of stroke as soon as possible. All&#xD;
      patients will be examined by CT and CTA or MRI and MRA on day 1 and in any case of clinical&#xD;
      deterioration to exclude intracranial haemorrhage and to assess recanalization of the&#xD;
      occluded vessel (using the thrombolysis in myocardial infarction (TIMI) grading system).&#xD;
      Clinical outcome will be evaluated on day 1 and at 3 months using the National Institute of&#xD;
      Health Stroke Scale (NIHSS) score, modified Rankin Scale score (mRS), Barthel Index (BI), and&#xD;
      assessing adverse events and quality of life. The proportion of patients with favourable&#xD;
      outcome (mRS 0 to 2) at 3 months after IVT and IAT will serve as the primary outcome measure.&#xD;
      In addition, subgroup analyses will be performed stratified by NIHSS, location of vessel&#xD;
      occlusion, time to hospital admission and time to treatment. Secondary outcome measures will&#xD;
      include quality of life and the proportion of patients with an excellent outcome (mRS 0 or 1)&#xD;
      at 3 months, BI 75 to 100 at 3 months, mortality at 3 months, rapid neurological improvement&#xD;
      during the first 24 hours, complete or partial recanalization, and symptomatic intracranial&#xD;
      haemorrhage.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2007</start_date>
  <completion_date type="Actual">December 2015</completion_date>
  <primary_completion_date type="Actual">March 2015</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>overall frequency of favourable clinical outcome (modified Rankin Scale 0 to 2), and unfavourable clinical outcome or death (modified Rankin Scale 3 to 6)</measure>
    <time_frame>Day 90</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>subgroup analyses will be performed stratified by NIHSS score</measure>
    <time_frame>Day 90</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Excellent functional clinical outcome (modified Rankin Scale 0 or 1) and quality of life (measured by EuroQol and Stroke specific Quality of Life Scale)</measure>
    <time_frame>Day 90</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All causes of mortality</measure>
    <time_frame>Day 90</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with rapid neurological improvement (more than 4 points on the NIHSS) during the first 24 hours after thrombolysis.</measure>
    <time_frame>Day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complete or partial recanalization of the occluded artery (TIMI grade 2 or 3) assessed by CTA or MRA.</measure>
    <time_frame>Day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Symptomatic intracranial haemorrhages up to 24 hours after thrombolysis defined as homogeneous areas of haemorrhage, with or without mass effect or intraventricular extension with neurological deterioration</measure>
    <time_frame>Day 1</time_frame>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">1476</enrollment>
  <condition>Ischemic Stroke</condition>
  <arm_group>
    <arm_group_label>1 1 (Liv*)</arm_group_label>
    <description>i.v. thrombolysis with rtPA</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2 (L*)</arm_group_label>
    <description>intraarterial thrombolysis</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Intravenous Thrombolysis</intervention_name>
    <description>i.V. thrombolysis with rtPa</description>
    <arm_group_label>1 1 (Liv*)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Intraarterial Thrombolysis</intervention_name>
    <description>Endovascular treatment with i.a. Urokinase or i.a. rtPA or mechanical recanalization techniques</description>
    <arm_group_label>2 (L*)</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with acute ischemic stroke treated with intravenous or intra-arterial thrombolysis&#xD;
        in a Swiss Stroke Unit.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age ≥ 18 years&#xD;
&#xD;
          -  Intracranial arterial occlusion confirmed by conventional angiography, MRA or CTA&#xD;
&#xD;
          -  National Institute of health Stroke Scale (NIHSS) score ≥ 4 or isolated aphasia or&#xD;
             hemianopia&#xD;
&#xD;
          -  Time to treatment &lt; 6 hours&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
          -  Intracranial haemorrhage on CT scn or MRI&#xD;
&#xD;
          -  History of intracranial haemorrhage or subarachnoid haemorrhage&#xD;
&#xD;
          -  Platelet count &lt; 100'000&#xD;
&#xD;
          -  International normalized ration (INR) &gt; 1.5&#xD;
&#xD;
          -  Partial thromboplastin time (PTT) &gt; 1.5 times the normal value&#xD;
&#xD;
          -  Known hereditary of acquired haemorrhagic diathesis&#xD;
&#xD;
          -  Pre-existing neurological deficit (mRS&gt;2)&#xD;
&#xD;
          -  Previous stroke that might interfere with the neurological assessment (mRS &gt;2)&#xD;
&#xD;
          -  Active gastric ulcer&#xD;
&#xD;
          -  Major trauma within the preceding 3 months&#xD;
&#xD;
          -  Major surgery within the past 4 weeks&#xD;
&#xD;
          -  Childbirth within the previous 4 weeks&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Uncontrolled hypertension (&gt;185/10 on repeated measures despite antihypertensive&#xD;
             medication)&#xD;
&#xD;
          -  Severe systemic disease with poor prognosis (e.g. cancer, severe heart failure)&#xD;
&#xD;
          -  Intracranial neoplasm&#xD;
&#xD;
          -  Combined IVT and IAT&#xD;
&#xD;
          -  Combined Intravenous and Ultrasound Thrombolysis&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marcel Arnold, MD Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dep. of Neurology, Bern University Hospital, Switzerland</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Krassen Nedeltechev, MD Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kantonsspital Aarau, Switzerland</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dep. of Neurology, Bern University Hospital</name>
      <address>
        <city>Bern</city>
        <zip>3010</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>April 2016</verification_date>
  <study_first_submitted>December 18, 2008</study_first_submitted>
  <study_first_submitted_qc>December 18, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 19, 2008</study_first_posted>
  <last_update_submitted>April 11, 2016</last_update_submitted>
  <last_update_submitted_qc>April 11, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 13, 2016</last_update_posted>
  <responsible_party>
    <name_title>PD Dr. Marcel Arnold, Oberarzt</name_title>
    <organization>Dep. of Neurology, Bern University Hospital</organization>
  </responsible_party>
  <keyword>ischemic stroke</keyword>
  <keyword>endovascular treatment</keyword>
  <keyword>Thrombolysis</keyword>
  <keyword>outcome</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
    <mesh_term>Ischemic Stroke</mesh_term>
    <mesh_term>Cerebral Infarction</mesh_term>
    <mesh_term>Ischemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

